Author Archive: Daniel Seaton

Daniel Seaton

Daniel Seaton is Manager of Event & Health Communications, working on communications for BIO’s events and health care policy issues. Prior to joining BIO in August 2013, he spent four years in communications at the Pharmaceutical Research and Manufacturers of America. The best part of his job is educating audiences about the many benefits the bioscience industry produces for patients, consumers, and the economy as a whole. Daniel enjoys hiking, camping, and, when he can find a game, playing bridge. Having grown up in New Mexico, one of his favorite foods is roasted green chile. He recently completed a Master’s degree in communications at Georgetown University.

Latest Posts

Missed #BIO2015? There’s an app for that.

bio2015 virtual attendee package

If you missed out on BIO 2015 in Philadelphia last month – or didn’t get the chance to go to all the sessions you wanted – I’ve got the solution for you. For the first time ever, select educational programming is now available in our Virtual Attendee Package, featuring sessions from tracks including Business Development & Finance, Digital Health, Oncology, Infectious Disease, Personalized Medicine & Diagnostics, and more. You’ll be able to hear from speakers Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO Innovation Zone Company Snapshots: AreteX Engineering

BIO Innovation Zone

This month in Philadelphia at the BIO International Convention, BIO will be partnering with the National Science foundation (NSF) and the National Institutes of Health (NIH) to host the 2nd annual, newly-expanded BIO Innovation Zone. The Zone will feature Small Business Innovation Research (SBIR) funded early-stage biotech companies. The SBIR/STTR program provides U.S. federal funding to small businesses engaged in research with the potential for commercialization. Each of the companies has been rigorously vetted through the SBIR/STTR review process Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

BIO Innovation Zone Company Snapshots: Delsys, Immunetics, and Advanced Plasma Products

BIO Innovation Zone

Next week in Philadelphia at the BIO International Convention, BIO will be partnering with the National Institutes of Health (NIH) and the National Science Foundation (NSF) to host the 2nd annual, newly-expanded BIO Innovation Zone. The Zone will feature Small Business Innovation Research (SBIR) funded early-stage biotech companies. The SBIR/STTR program provides U.S. federal funding to small businesses engaged in research with the potential for commercialization. Each of the companies has been rigorously vetted through the SBIR/STTR review process prior to Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

4 Days Until BIO 2015: Vitae CEO Excited for BIO to Come to Philadelphia

BIO International Convention

Jeff Hatfield, CEO of Vitae Pharmaceuticals, welcomed BIO 2015 to his home town of Philly through a blog post in Life Sci VC, sharing his thoughts on the city’s historic legacy of innovation and collaboration. Hatfield noted: “Innovation is what defines our industry; and collaboration – well, more than 30 thousand collaboration partnering meetings are expected to occur at the convention next week.” The blog post explains that Philadelphia is undergoing an important transition in the Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO Innovation Zone Company Snapshots: Giner, GigaGen, and Synthonics

BIO Innovation Zone

Later this month in Philadelphia at the BIO International Convention, BIO will be partnering with the National Institutes of Health (NIH) and the National Science Foundation (NSF) to host the 2nd annual, newly-expanded BIO Innovation Zone. The Zone will feature Small Business Innovation Research (SBIR) funded early-stage biotech companies. The SBIR/STTR program provides U.S. federal funding to small businesses engaged in research with the potential for commercialization. Each of the companies has been rigorously vetted through the SBIR/STTR review process Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,